Rebimastat
DCTPepD ID DCTPepD0043
Active Ingredients Rebimastat
Description A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.
Synonyms BMS-275291; D2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; Rebimastat
Disease Lung cancer, Prostate cancer
Classification
MMP inhibitor Peptide and derivative
Structure Information
Molecular Formula C23H41N5O5S
Molecular Weight 499.7
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name (2S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide
InChI InChI=1S/C23H41N5O5S/c1-13(2)12-14(17(29)26-16(19(31)24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,34H,10-12H2,1-9H3,(H,24,31)(H,25,30)(H,26,29)/t14-,15-,16+/m0/s1
InChI_Key GTXSRFUZSLTDFX-HRCADAONSA-N
SMILES CC(C[C@@H](C(N[C@H](C(NC)=O)C(C)(C)C)=O)NC([C@H](CCN(C1=O)C(C(C)(N1C)C)=O)S)=O)C
External Codes
PubChem CID 9913881
DrugBank Accession Number DB06573
NCI Thesaurus Code C1875
UNII 1B47R6ZX4K GSRS
CAS 259188-38-0
Drug approval
Drug indication
Investigated for use/treatment in lung cancer and prostate cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00040755 | Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer | Adenocarcinoma of the Prostate; Bone Metastases; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer | Phase 2 | Treatment |
| NCT00039104 | A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer | Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer | Phase 2 | Treatment |
| NCT00024024 | A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma | Sarcoma | Phase 1/2 | Treatment |
| NCT00006229 | A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer | Lung Cancer | Phase 2/3 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
